Metabolic & obesity · Phase III

Top sponsors

• Takeda 35 programs
• NovoThirteen 25 programs
• Eli Lilly and 20 programs
• Regeneron UK 12 programs
• Boehringer Ingelheim 10 programs
• Novo Nordisk A/S 10 programs
• AstraZeneca 9 programs
• LEXICON PHARMACEUTICALS 8 programs
• Eli Lilly and 6 programs
• HOFFMANN-LA ROCHE 6 programs
• George Institute for 5 programs
• Kailera Therapeutics 5 programs

1. 1378-0041

   Boehringer Ingelheim

   Type 2 diabetes, hypertension, cardiovascular disease

   phase 3 · small molecule · active

   1 trial →

2. 1404-0038

   Boehringer Ingelheim

   Obesity

   phase 3 · small molecule · active

   1 trial →

3. 1404-0040

   Boehringer Ingelheim

   Obesity

   phase 3 · small molecule · active

   1 trial →

4. 1404-0041

   Boehringer Ingelheim

   Obesity, Diabetes mellitus type II

   phase 3 · small molecule · active

   1 trial →

5. 1404-0056

   Boehringer Ingelheim

   Obesity

   phase 3 · small molecule · active

   1 trial →

6. 14V-MC-JAJK

   Eli Lilly Co.

   Diabetes Mellitus, Type 1

   phase 3 · small molecule · active

   1 trial →

7. 2-mg Intravitreous Aflibercept Injection

   Regeneron UK Limited

   Proliferative Diabetic Retinopathy

   phase 3 · small molecule · completed

   1 trial →

8. 2.0 mg intravitreal aflibercept

   Regeneron UK Limited

   Diabetic Macular Edema

   phase 3 · small molecule · completed

   1 trial →

9. 20220196

   Amgen

   Atherosclerotic cardiovascular disease (ASCVD) and obesity or overweight

   phase 3 · small molecule · active

   1 trial →

10. 20230225

    Amgen

    "Moderate to severe obstructive sleep apnea (OSA) in adults living with overweight or obesity"

    phase 3 · small molecule · active

    1 trial →

11. 20230227

    Amgen

    Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity

    phase 3 · small molecule · active

    1 trial →

12. 21177

    Bayer AG

    Non-diabetic chronic kidney disease

    phase 3 · small molecule · active

    1 trial →

13. 8 mg aflibercept (BAY 86-5321) (High Dose)

    Regeneron UK Limited

    Diabetic Macular Edema

    phase 3 · small molecule · completed

    1 trial →

14. ANDA219975 + ANDA220011

    Lxo Ireland Designated Activity Company

    Type 2 Diabetes

    phase 3 · small molecule · active

    1 trial →

15. APHP180591

    Pari Pharma GmbH

    Adults Non Diabete Remission (NDR) Type 2 Diabete (T2D) patients 1 to 5 years after bariatric surgery

    phase 3 · small molecule · active

    1 trial →

16. Aflibercept

    Hoffmann-La Roche

    Diabetic Macular Edema

    phase 3 · small molecule · completed

    1 trial →

17. Aleglitazar

    Hoffmann-La Roche

    Diabetes Mellitus Type 2

    phase 3 · small molecule · completed

    2 trials →

18. Alirocumab

    Regeneron UK Limited

    Type2 Diabetes

    phase 3 · small molecule · completed

    1 trial →

19. Alogliptin

    Takeda

    Diabetes Mellitus

    phase 3 · small molecule · completed

    9 trials →

20. Alogliptin

    Takeda

    Type 2 Diabetes Mellitus

    phase 3 · small molecule · completed

    5 trials →

21. Alogliptin Benzoate

    Takeda

    Diabetes Mellitus, Type 2

    phase 3 · small molecule · completed

    1 trial →

22. Alogliptin and glimepiride

    Takeda

    Type 2 Diabetes Mellitus

    phase 3 · small molecule · completed

    2 trials →

23. Alogliptin and glyburide

    Takeda

    Diabetes Mellitus

    phase 3 · small molecule · completed

    1 trial →

24. Alogliptin and insulin

    Takeda

    Diabetes Mellitus

    phase 3 · small molecule · completed

    1 trial →

25. Alogliptin and metformin

    Takeda

    Type 2 Diabetes Mellitus

    phase 3 · small molecule · completed

    1 trial →

26. Alogliptin and metformin

    Takeda

    Diabetes Mellitus

    phase 3 · small molecule · completed

    1 trial →

27. Alogliptin and pioglitazone

    Takeda

    Diabetes Mellitus

    phase 3 · small molecule · completed

    2 trials →

28. Alogliptin and pioglitazone

    Takeda

    Type 2 Diabetes Mellitus

    phase 3 · small molecule · completed

    2 trials →

29. Alogliptin and voglibose

    Takeda

    Type 2 Diabetes Mellitus

    phase 3 · small molecule · completed

    2 trials →

30. Aramchol free acid

    Galmed Pharmaceuticals

    Nonalcoholic Steatohepatitis (NASH)

    phase 3 · small molecule · on hold

    1 trial →

31. BAT5906 injection

    Bio-Thera Solutions

    Diabetic Macular Edema (DME)

    phase 3 · small molecule · active

    1 trial →

32. BI 10773

    Boehringer Ingelheim

    Diabetes Mellitus, Type 2

    phase 3 · small molecule · completed

    1 trial →

33. BT-001

    CATALYST PHARMACEUTICALS, INC.

    Type2 Diabetes

    phase 3 · other · terminated

    1 trial →

34. Betamethasone Microsphere (DE-102） Low Dose

    Santen Oy

    Diabetic Macular Edema

    phase 3 · small molecule · completed

    1 trial →

35. Bevacizumab

    Hospital Authority, Hong Kong

    Proliferative Diabetic Retinopathy

    phase 3 · small molecule · completed

    1 trial →

36. Biological/Vaccine

    Vertex Pharmaceuticals (Australia) Pty.

    Type 1 Diabetes

    phase 3 · mab · active

    1 trial →

37. Botulinum toxin type A

    Hospital Authority, Hong Kong

    Obesity

    phase 3 · small molecule · active

    1 trial →

38. CKD-501 0.5mg

    Hong Kong Baptist University

    Diabetes Mellitus, Type 2

    phase 3 · small molecule · completed

    2 trials →

39. CSII (Insulin Pump) plus DAFNE

    United Therapeutics Europe Ltd

    Type 1 Diabetes

    phase 3 · other · completed

    1 trial →

40. CT-L03-301

    Celltrion Healthcare Australia Pty Ltd

    Type 2 diabetes mellitus (T2DM)

    phase 3 · small molecule · active

    1 trial →

41. Cadisegliatin 800 mg QD

    vTv Therapeutics

    Diabetes Mellitus, Type 1

    phase 3 · small molecule · active

    1 trial →

42. Canagliflozin

    Janssen Cilag International NV

    Diabetes Mellitus, Type 2

    phase 3 · small molecule · completed

    1 trial →

43. Capsaicin

    BRIGHT MINDS BIOSCIENCES INC.

    Diabetic Polyneuropathy

    phase 3 · small molecule · completed

    1 trial →

44. D20180102

    Pari Pharma GmbH

    Vascular calcification and type 1 diabetes

    phase 3 · small molecule · active

    1 trial →

45. Dapagliflozin

    AstraZeneca

    Type 2 Diabetes Mellitus

    phase 3 · small molecule · completed

    2 trials →

46. Dapagliflozin

    AstraZeneca

    Type 2 Diabetes

    phase 3 · small molecule · completed

    3 trials →

47. Dapagliflozin 10 mg

    AstraZeneca

    Diabetes Mellitus, Non-Insulin-Dependent

    phase 3 · small molecule · completed

    1 trial →

48. Dapagliflozin 10 mg

    AstraZeneca

    Type 2 Diabetes Mellitus

    phase 3 · small molecule · terminated

    1 trial →

Frequently asked questions